VYNE Therapeutics
VYNE
106 hedge funds and large institutions have $160M invested in VYNE Therapeutics in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 11 reducing their positions, and 22 closing their positions.
427% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 11
73% more capital invested
Capital invested by funds: $92.7M → $160M (+$67.5M)
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
14% more funds holding
Funds holding: 93 → 106 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.09% less ownership
Funds ownership: 0.79% → 0.7% (-0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$30.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$12.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 4 |
BlackRock
New York
|
+$9.87M |
| 5 |
6CM
683 Capital Management
New York
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.43M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$3.92M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.83M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.68M |
| 5 |
O
OrbiMed
New York
|
-$2.18M |
VYNE Hedge Fund Activity: Q2 2020 in Review
106 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2020, worth a combined $160M — up 73% from $92.7M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new VYNE positions and 22 closed out — a net gain of 13 holders — while 58 added to existing stakes and 11 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $30.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.43M sold.
- 106 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2020, up from 93 in Q1 2020.
- Funds reported $160M of VYNE Therapeutics stock for Q2 2020, up 73% quarter-over-quarter.
- 35 funds opened new VYNE Therapeutics positions in Q2 2020 and 22 closed out, a net change of +13 holders.
- The largest VYNE Therapeutics buyer in Q2 2020 was Perceptive Advisors, an estimated $30.5M added.
- The largest VYNE Therapeutics seller in Q2 2020 was Great Point Partners, an estimated $4.43M sold.
Based on aggregated 13F filings for Q2 2020.